<DOC>
	<DOCNO>NCT01254305</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability Levomilnacipran ER treatment fatigue associate major depressive disorder ( MDD ) .</brief_summary>
	<brief_title>Safety Efficacy Levomilnacipran ER ( F2695 SR ) Adults With Fatigue Associated With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Men woman , 1865 year old Currently meet Diagnostic Statistical Manual Mental Disorders , Fourth EditionText Revision ( DSMIVTR ) criteria Major Depressive Disorder The patient 's current depressive episode must least 4 week duration Women pregnant , woman breastfeed study , woman childbearing potential practicing reliable method birth control Patients history meeting DSMIVTR criterion : 1. manic hypomanic episode ; 2. schizophrenia psychotic disorder ; 3. obsessivecompulsive disorder . Patients consider suicide risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Depression</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>